About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Common Allergy Medication Reduces Relapses in Patients With Neuromyelitis Optica

by Anjali Aryamvally on February 3, 2018 at 3:35 PM
Font : A-A+

Common Allergy Medication Reduces Relapses in Patients With Neuromyelitis Optica

Bottom Line: The addition of cetirizine, a popular allergy medication sold under the brand name Zyrtec, to standard therapy is safe, well-tolerated, and may reduce relapses in patients with neuromyelitis optica (NMO), shows new study. NMO is a rare but severe disease that causes inflammation and demyelination, primarily in the optic nerve, spinal cord, and brainstem.

Results: The primary endpoint was the annualized relapse rate (ARR) while on the same disease-modifying therapy before starting cetirizine compared with after taking cetirizine. The ARR before cetirizine was 0.4±0.80 and after cetirizine was 0.1±0.24 (p=0.047).

Advertisement


Why the Research Is Interesting: Current standard treatments for NMO have focused on lymphocytes; however, granulocyte infiltration has been shown to play an important role in NMO-related inflammatory destruction. In addition to its antihistaminic functions, cetirizine is known to have eosinophil-stabilizing properties. Cetirizine also has a myriad of effects on other immune system components, including inhibition of lymphocyte and monocyte chemotaxis. Animal model work demonstrated that the development of NMOSD-type lesions could be blocked with the administration of cetirizine, so it was exciting to see if it might be safe and effective for human NMO patients.

Who: This pilot, open-label, add-on trial of cetirizine followed 16 NMO patients taking 10mg/day of orally administered cetirizine for one year.
Advertisement

When: Participants were enrolled/followed from April 2014- February 2016.

What: The study measured the ARR of patients prior to starting cetirizine compared with after taking cetirizine.

How: Participants started cetirizine 10mg orally daily and continued for one year, in addition to their established NMOSD disease-modifying therapy. They were monitored for new neurologic episodes and potential adverse events related to the study drug. Formal relapse assessments as well as the Epworth Sleepiness Scale were completed at 3, 6, 9 and 12 months.

Study Conclusions: Cetirizine is safe, well-tolerated, and may help prevent relapses in NMO. The open-label design and small sample size in this trial preclude definitive conclusions; however, these results warrant further study. Cetirizine given chronically may be able to prevent the activation and chemotaxis of eosinophils and other inflammatory cells, should the beginning of a relapse cascade occur; however, a larger sample size with more frequent specimen collection would be required to determine this definitively.

Paper Title: Open-label, add-on trial of cetirizine for neuromyelitis optica

Said Mount Sinai's Dr. Ilana Katz Sand of the research:

"We were pleased to find that cetirizine was safe and well-tolerated in our population of NMO patients. While the study's open-label design and small sample size preclude definitive conclusions, we did detect a signal that suggested cetirizine may be of benefit. We look forward to future research on this topic."



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Health Benefits of Sea Buckthorn
Contraceptive Pills in Polycystic Ovary Syndrome (PCOS) Curtail Type 2 Diabetes Risk
Mushroom May Help Cut Down the Odds of Developing Depression
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Allergy Drug Toxicity Healthy Living Dealing with Pollen Allergy Remedies for Seasonal Allergy Relief Choose The Right Over-the-Counter Drugs for Allergy Optic Neuritis Allergy - Symptom Evaluation Stay Well This Winter 

Recommended Reading
Eculizumab may Prevent Inflammation in Eye Nerves and Spinal Cord Among Neuromyelitis Optica Patients: Mayo Clinic Research
Researchers at Mayo Clinic have identified a new treatment for patients suffering from ......
Breathe-in or Ingestible Antibody can Help Prevent Allergy, Asthma
The ingestible or inhalable antibody prevents allergic reactions and asthma in adults, by binding .....
Children with Asthma or Food Allergy at Risk of Anxiety Disorder
Children suffering from chronic illnesses like asthma, food allergy, epilepsy, diabetes or juvenile ...
Helminths Increase Risk of Allergy, Asthma in Humans
The intestinal worms that are usually found in animals but if found in humans, it increases the ......
Allergy
An allergy is a hypersensitive disorder of immune system. Substances that often cause allergic react...
Allergy - Symptom Evaluation
An allergic reaction may be mild or severe. It usually involves the skin, respiratory system, eyes,...
Choose The Right Over-the-Counter Drugs for Allergy
Over-the-counter (OTC) drugs can be bought without a prescription. OTC allergy medications are for t...
Dealing with Pollen Allergy
The plants around you that give you sniffles in your nose at specific time of the year are the sourc...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Optic Neuritis
Optic neuritis is acute inflammation of the optic nerve. Optic nerve connects the eye to the brain a...
Remedies for Seasonal Allergy Relief
Understanding the cause and mechanism of seasonal allergy can help in choosing the right treatment. ...
Stay Well This Winter
Winter is associated with staying huddled indoors, people scurrying home to escape the piercing wint...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use